Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 365

1.

Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption.

Wang CY, Wong WW, Tsai HC, Chen YH, Kuo BS, Lynn S, Blazkova J, Clarridge KE, Su HW, Lin CY, Tseng FC, Lai A, Yang FH, Lin CH, Tseng W, Lin HY, Finstad CL, Wong-Staal F, Hanson CV, Chun TW, Liao MJ.

N Engl J Med. 2019 Apr 18;380(16):1535-1545. doi: 10.1056/NEJMoa1802264.

PMID:
30995373
2.

Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.

Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ.

Liver Transpl. 2016 Mar;22(3):287-97. doi: 10.1002/lt.24349.

3.

Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P.

Hepatology. 2014 Nov;60(5):1508-18. doi: 10.1002/hep.27196. Epub 2014 Jul 30.

4.

Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.

Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, Amorosa V, Bhattacharya D, Coughlin K, Wong-Staal F, Glesby MJ; AIDS Clinical Trials Group A5277 Protocol Team.

J Infect Dis. 2014 Mar 1;209(5):658-67. doi: 10.1093/infdis/jit503. Epub 2013 Sep 16.

5.

ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection.

Hochreiter J, Lapham J, Wong-Staal F, McKelvy J, Sulkowski M, Glesby MJ, Johnson VA, Morse GD.

Antivir Ther. 2013;18(3):329-36. doi: 10.3851/IMP2354. Epub 2012 Sep 6.

PMID:
22954720
6.

Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor.

Mittapalli GK, Zhao F, Jackson A, Gao H, Lee H, Chow S, Kaur MP, Nguyen N, Zamboni R, McKelvy J, Wong-Staal F, Macdonald JE.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):4955-61. doi: 10.1016/j.bmcl.2012.06.038. Epub 2012 Jun 19.

PMID:
22784640
7.

A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes.

Haid S, Novodomsk√° A, Gentzsch J, Grethe C, Geuenich S, Bankwitz D, Chhatwal P, Jannack B, Hennebelle T, Bailleul F, Keppler OT, Poenisch M, Bartenschlager R, Hernandez C, Lemasson M, Rosenberg AR, Wong-Staal F, Davioud-Charvet E, Pietschmann T.

Gastroenterology. 2012 Jul;143(1):213-22.e5. doi: 10.1053/j.gastro.2012.03.036. Epub 2012 Mar 27.

PMID:
22465429
8.

Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, Wyles DL.

J Infect Dis. 2012 Feb 15;205(4):656-62. doi: 10.1093/infdis/jir802.

9.

Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.

Mittapalli GK, Jackson A, Zhao F, Lee H, Chow S, McKelvy J, Wong-Staal F, Macdonald JE.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6852-5. doi: 10.1016/j.bmcl.2011.09.019. Epub 2011 Sep 16.

PMID:
21978675
10.

Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.

Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA.

J Virol. 2011 Jan;85(1):596-605. doi: 10.1128/JVI.01592-10. Epub 2010 Oct 20.

11.

Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.

Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F.

J Hepatol. 2011 Jan;54(1):48-55. doi: 10.1016/j.jhep.2010.06.024. Epub 2010 Aug 21.

PMID:
20932595
12.

Targeting HCV entry for development of therapeutics.

Wong-Staal F, Syder AJ, McKelvy JF.

Viruses. 2010 Aug;2(8):1718-33. doi: 10.3390/v2081718. Epub 2010 Aug 18.

13.

Hepatitis C virus infection of neuroepithelioma cell lines.

Fletcher NF, Yang JP, Farquhar MJ, Hu K, Davis C, He Q, Dowd K, Ray SC, Krieger SE, Neyts J, Baumert TF, Balfe P, McKeating JA, Wong-Staal F.

Gastroenterology. 2010 Oct;139(4):1365-74. doi: 10.1053/j.gastro.2010.06.008. Epub 2010 Jun 9.

14.

A method for detecting and preventing negative RNA interference in preparation of lentiviral vectors for siRNA delivery.

Zhou D, Zhang J, Wang C, Bliesath JR, He Q, Yu D, Li-He Z, Wong-Staal F.

RNA. 2009 Apr;15(4):732-40. doi: 10.1261/rna.985209. Epub 2009 Feb 25.

15.

Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy.

Yu DH, Macdonald J, Liu G, Lee AS, Ly M, Davis T, Ke N, Zhou D, Wong-Staal F, Li QX.

PLoS One. 2008;3(12):e3951. doi: 10.1371/journal.pone.0003951. Epub 2008 Dec 16.

16.

Screening of small-molecule compounds as inhibitors of HCV entry.

Yang JP, Zhou D, Wong-Staal F.

Methods Mol Biol. 2009;510:295-304. doi: 10.1007/978-1-59745-394-3_22.

PMID:
19009270
17.

Comparisons of RNAi approaches for validation of human RNA helicase A as an essential factor in hepatitis C virus replication.

He QS, Tang H, Zhang J, Truong K, Wong-Staal F, Zhou D.

J Virol Methods. 2008 Dec;154(1-2):216-9. doi: 10.1016/j.jviromet.2008.08.005. Epub 2008 Sep 30.

PMID:
18782589
18.

Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186.

Falkenstein IA, Cheng L, Wong-Staal F, Tammewar AM, Barron EC, Silva GA, Li QX, Yu D, Hysell M, Liu G, Ke N, Macdonald JE, Freeman WR.

Curr Eye Res. 2008 Jul;33(7):599-609. doi: 10.1080/02713680802226582.

19.

Oncolytic virotherapy as a personalized cancer vaccine.

Li QX, Liu G, Wong-Staal F.

Int J Cancer. 2008 Aug 1;123(3):493-9. doi: 10.1002/ijc.23692. Review.

20.

Selective anticancer strategies via intervention of the death pathways relevant to cell transformation.

Li QX, Yu DH, Liu G, Ke N, McKelvy J, Wong-Staal F.

Cell Death Differ. 2008 Aug;15(8):1197-210. doi: 10.1038/cdd.2008.48. Epub 2008 Apr 25. Review.

21.

Generation of shRNA pool library: a revision of the biological technique from the viewpoint of chemistry.

Zhou D, Wang C, Zhang J, Bliesath J, He QS, Ke N, Yu D, Li Q, Zhang LH, Wong-Staal F.

Chembiochem. 2008 Jun 16;9(9):1365-7. doi: 10.1002/cbic.200800049. No abstract available.

PMID:
18435449
22.

Biochemical characterization of genetic mutations of GPR56 in patients with bilateral frontoparietal polymicrogyria (BFPP).

Ke N, Ma H, Diedrich G, Chionis J, Liu G, Yu DH, Wong-Staal F, Li QX.

Biochem Biophys Res Commun. 2008 Feb 8;366(2):314-20. Epub 2007 Nov 26.

PMID:
18042463
23.

Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase.

Liu G, Grifman M, Macdonald J, Moller P, Wong-Staal F, Li QX.

J Endocrinol. 2007 Sep;194(3):569-78.

PMID:
17761896
24.

A more efficient RNAi inducible system for tight regulation of gene expression in mammalian cells and xenograft animals.

Zhang J, Wang C, Ke N, Bliesath J, Chionis J, He QS, Li QX, Chatterton JE, Wong-Staal F, Zhou D.

RNA. 2007 Aug;13(8):1375-83. Epub 2007 Jul 6.

25.

Orphan G protein-coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway.

Ke N, Sundaram R, Liu G, Chionis J, Fan W, Rogers C, Awad T, Grifman M, Yu D, Wong-Staal F, Li QX.

Mol Cancer Ther. 2007 Jun;6(6):1840-50.

26.

Ribozyme technology for cancer gene target identification and validation.

Li QX, Tan P, Ke N, Wong-Staal F.

Adv Cancer Res. 2007;96:103-43. Review.

PMID:
17161678
27.

Development of new RNAi therapeutics.

Liu G, Wong-Staal F, Li QX.

Histol Histopathol. 2007 Feb;22(2):211-7. doi: 10.14670/HH-22.211. Review.

PMID:
17149694
28.

Recent development of RNAi in drug target discovery and validation.

Liu G, Wong-Staal F, Li QX.

Drug Discov Today Technol. 2006 Autumn;3(3):293-300. doi: 10.1016/j.ddtec.2006.09.003.

PMID:
24980531
29.

RNA interference and potential applications.

Zhou D, He QS, Wang C, Zhang J, Wong-Staal F.

Curr Top Med Chem. 2006;6(9):901-11. Review.

PMID:
16787283
30.

A new inducible RNAi xenograft model for assessing the staged tumor response to mTOR silencing.

Ke N, Zhou D, Chatterton JE, Liu G, Chionis J, Zhang J, Tsugawa L, Lynn R, Yu D, Meyhack B, Wong-Staal F, Li QX.

Exp Cell Res. 2006 Sep 10;312(15):2726-34.

PMID:
16765945
31.

MDDD, a 4,9-diazapyrenium derivative, is selectively toxic to glioma cells by inducing growth arrest at G0/G1 independently of p53.

Yu DH, Macdonald J, Josephs S, Liu Q, Nguy V, Tor Y, Wong-Staal F, Li QX.

Invest New Drugs. 2006 Nov;24(6):489-98.

PMID:
16633716
32.

A novel RNAi library based on partially randomized consensus sequences of nuclear receptors: identifying the receptors involved in amyloid beta degradation.

Yang JP, Fan W, Rogers C, Chatterton JE, Bliesath J, Liu G, Ke N, Wang CY, Rhoades K, Wong-Staal F, Li QX.

Genomics. 2006 Sep;88(3):282-92. Epub 2006 May 2.

33.

Therapy with ribozyme to the proliferating cell nuclear antigen-ribozyme and 5-fluorouracil of experimental choroidal neovascularization in rats.

Kayikcioglu OR, Falkenstein I, Cheng L, Kozak I, La Bree L, Azen SP, Wong-Staal F, Paoni NF, Freeman WR.

J Ocul Pharmacol Ther. 2006 Feb;22(1):1-9.

PMID:
16503769
34.

NR4A1, 2, 3--an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis.

Li QX, Ke N, Sundaram R, Wong-Staal F.

Histol Histopathol. 2006 May;21(5):533-40. doi: 10.14670/HH-21.533. Review.

PMID:
16493583
35.

PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway.

Yu DH, Fan W, Liu G, Nguy V, Chatterton JE, Long S, Ke N, Meyhack B, Bruengger A, Brachat A, Wong-Staal F, Li QX.

Exp Cell Res. 2006 Apr 1;312(6):865-76. Epub 2006 Jan 17.

PMID:
16413018
36.

Expression, purification, and renaturation of bone morphogenetic protein-2 from Escherichia coli.

Long S, Truong L, Bennett K, Phillips A, Wong-Staal F, Ma H.

Protein Expr Purif. 2006 Apr;46(2):374-8. Epub 2005 Oct 27.

PMID:
16298141
37.

A 96-well surrogate survival assay coupled with a special short interfering RNA vector for assessing cancer gene targets with enhanced signal/noise ratio and its utility in HTS for cancer therapeutic targets.

Yu DH, Chatterton JE, Bliesath JR, Sundaram R, Ke N, Nguy V, Meyhack B, Wong-Staal F, Li QX.

Assay Drug Dev Technol. 2005 Aug;3(4):401-11.

PMID:
16180995
38.

The development and applications of nonradioactive plate-formatted DNA-binding assay for Ku70/80, a multifunctional DNA-binding protein complex.

Ma H, Thibault J, Lu Y, Whiting C, Long S, Lindwall G, Bennett K, Truong L, Aimes RT, Wong-Staal F.

Assay Drug Dev Technol. 2004 Oct;2(5):483-95.

PMID:
15671646
39.

Nuclear hormone receptor NR4A2 is involved in cell transformation and apoptosis.

Ke N, Claassen G, Yu DH, Albers A, Fan W, Tan P, Grifman M, Hu X, Defife K, Nguy V, Meyhack B, Brachat A, Wong-Staal F, Li QX.

Cancer Res. 2004 Nov 15;64(22):8208-12.

40.

Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach.

Waninger S, Kuhen K, Hu X, Chatterton JE, Wong-Staal F, Tang H.

J Virol. 2004 Dec;78(23):12829-37.

41.

RNA helicase A interacts with nuclear factor kappaB p65 and functions as a transcriptional coactivator.

Tetsuka T, Uranishi H, Sanda T, Asamitsu K, Yang JP, Wong-Staal F, Okamoto T.

Eur J Biochem. 2004 Sep;271(18):3741-51.

42.

Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus.

Hu X, Hipolito S, Lynn R, Abraham V, Ramos S, Wong-Staal F.

Nucleic Acids Res. 2004 Aug 27;32(15):4609-17. Print 2004.

43.

Transduction of cell lines and primary cells by FIV-packaged HIV vectors.

Morris KV, Gilbert J, Wong-Staal F, Gasmi M, Looney DJ.

Mol Ther. 2004 Jul;10(1):181-90.

44.

One-week 96-well soft agar growth assay for cancer target validation.

Ke N, Albers A, Claassen G, Yu DH, Chatterton JE, Hu X, Meyhack B, Wong-Staal F, Li QX.

Biotechniques. 2004 May;36(5):826-8, 830, 832-3.

45.

The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope.

Kan-Mitchell J, Bisikirska B, Wong-Staal F, Schaubert KL, Bajcz M, Bereta M.

J Immunol. 2004 May 1;172(9):5249-61.

46.

Arginine methylation of RNA helicase a determines its subcellular localization.

Smith WA, Schurter BT, Wong-Staal F, David M.

J Biol Chem. 2004 May 28;279(22):22795-8. Epub 2004 Apr 14.

47.

Generation of dendritic cells from lentiviral vector-transduced CD34+ cells from HIV+ donors.

Gruber A, Chen I, Kuhen KL, Wheat JC, Law P, Wong-Staal F.

J Med Virol. 2003 Jun;70(2):183-6.

PMID:
12696103
48.

Integrated approaches to therapeutic target gene discovery.

DeFife KM, Wong-Staal F.

Curr Opin Drug Discov Devel. 2002 Sep;5(5):683-9. Review.

PMID:
12630288
49.
50.

HIV-2 and SIV vector systems.

Gilbert JR, Wong-Staal F.

Somat Cell Mol Genet. 2001 Nov;26(1-6):83-98. Review.

PMID:
12465463

Supplemental Content

Loading ...
Support Center